A federal judge denied Amgen Inc.’s effort to block the sale of Sandoz’s recently approved biosimilar version of Neupogen. U.S. District Judge Richard Seeborg in San Francisco on Thursday rejected Amgen’s bid for a preliminary injunction blocking Novartis’ Sandoz from selling its Zarxio (filgrastim), a biosimilar version of Amgen’s Neupogen …